Press releases

Oct 20, 2017
Promising preliminary long-term data for WTX101 in Wilson Disease highlighted at The Liver Meeting®
Read more

Oct 06, 2017
Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
Read more

Oct 01, 2017
Promising preliminary long-term data from WTX101 Phase 2 extension study to be presented at AASLD Annual Meeting
Read more

Aug 24, 2017
Wilson Therapeutics AB (publ) Interim Report January 1 – June 30, 2017
Read more

Aug 17, 2017
Wilson Therapeutics to host conference call to provide second quarter 2017 business update
Read more

Jun 09, 2017
Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS
Read more

Jun 08, 2017
Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
Read more

May 22, 2017
Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn Odlander
Read more

May 19, 2017
Wilson Therapeutics to present at Bioequity Europe
Read more

May 17, 2017
Report from the annual general meeting of Wilson Therapeutics AB (publ)
Read more

May 17, 2017
Wilson Therapeutics AB (publ) Interim Report January 1 – March 31, 2017
Read more

May 10, 2017
Wilson Therapeutics to host conference call to provide first quarter 2017 business update
Read more

Apr 25, 2017
Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
Read more

Apr 24, 2017
Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting
Read more

Apr 19, 2017
Wilson Therapeutics’ 2016 Annual Report published
Read more

Apr 18, 2017
Notice of annual general meeting in Wilson Therapeutics
Read more

Apr 05, 2017
Final Phase 2 results for WTX101 accepted as a late-breaker presentation at EASL Annual Meeting
Read more

Mar 09, 2017
Wilson Therapeutics to present at the Carnegie Healthcare Seminar 2017
Read more

Feb 23, 2017
Wilson Theraputics AB (publ) Year-end Report 2016
Read more

Jan 18, 2017
Report from the extraordinary general meeting of Wilson Therapeutics AB (publ)
Read more